Publications by authors named "N Lopez-Holgado"
Hematopoietic stem cell transplantation (HSCT) using umbilical cord blood (UCB) progenitors is increasingly being used. One of the problems that may arise after UCB transplantation is an impaired engraftment. Either intrabone (IB) injection of hematopoietic progenitors or mesenchymal stem cell (MSC) coadministration has been proposed among the strategies to improve engraftment.
View Article and Find Full Text PDFArticle Synopsis
- * It involved isolating MSC from healthy donors and analyzing their effects on damaged stromal cultures, focusing on molecule markers like SDF1 and osteopontin related to bone marrow support.
- * Results showed that MSC could successfully lodge in severely damaged BM stroma and helped restore the expression of important supporting molecules, with MSC primarily found at the injection site, indicating a localized effect.
Background Aims: The aim of this study was to compare prospectively the vasculogenic capacity of two cell sources, monocytes and CD133+ cells.
Methods: Cells were obtained from healthy donors by adherence or magnetic selection. Animals studies were performed in a model of hind limb ischemia and different groups were established according to type and number of cells infused.
To address a number of questions regarding the experimental use of bone marrow (BM) stem cells in hindlimb ischemia, including which is the best cell type (e.g., purified hematopoietic stem cell or monocytes), the best route of delivery [intramuscular (IM) or intravenous (IV)], and the mechanism of action (transdifferentiation or paracrine effects), we have compared the neovascularization capacities of CD133(+) stem cells and monocytes (CD11b(+)) from the BM of Tie2-GFP mice either via IV or IM in a murine severe hindlimb ischemia model.
View Article and Find Full Text PDF